{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Apigenin", "Hyperuricemia", "Inflammation", "Luteolin", "Luteoloside", "Uric acid transporter"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "34244900", "DateCompleted": {"Year": "2021", "Month": "12", "Day": "31"}, "DateRevised": {"Year": "2021", "Month": "12", "Day": "31"}, "Article": {"ArticleDate": [{"Year": "2021", "Month": "07", "Day": "09"}], "Language": ["eng"], "ELocationID": ["10.1007/s10787-021-00844-5"], "Journal": {"ISSN": "1568-5608", "JournalIssue": {"Volume": "29", "Issue": "4", "PubDate": {"Year": "2021", "Month": "Aug"}}, "Title": "Inflammopharmacology", "ISOAbbreviation": "Inflammopharmacology"}, "ArticleTitle": "Active components from Lagotis brachystachya maintain uric acid homeostasis by inhibiting renal TLR4-NLRP3 signaling in hyperuricemic mice.", "Pagination": {"StartPage": "1187", "EndPage": "1200", "MedlinePgn": "1187-1200"}, "Abstract": {"AbstractText": ["Lagotis brachystachya Maxim is a herb widely used in traditional Tibetan medicine. Our previous study indicated that total extracts from Lagotis brachystachya could lower uric acid levels. This study aimed to further elucidate the active components (luteolin, luteoloside and apigenin) isolated from Lagotis brachystachya and the underlying mechanism in vitro and in vivo. The results showed that treatment with luteolin and luteoloside reversed the reduction of organic anion transporter 1 (OAT1) levels, while apigenin attenuated the elevation of urate transporter 1 (URAT1) and glucose transporter 9 (GLUT9) levels in uric acid-treated HK-2 cells, which was consistent with the finding in the kidneys of potassium oxonate (PO)-induced mice. On the other hand, hepatic xanthine oxidase activity was inhibited by the components. In addition, all of these active components improved the morphology of the kidney in hyperuricemic mice. Moreover, molecular docking showed that luteolin, luteoloside and apigenin could bind Toll-like receptor 4 (TLR4) and NLR family pyrin domain containing 3 (NLRP3). Congruently, western blot analysis showed that the components inhibited TLR4/myeloid differentiation primary response 88 (MyD88)/NLRP3 signaling. In conclusion, these results indicated that luteolin, luteoloside and apigenin could attenuate hyperuricemia by decreasing the production and increasing the excretion of uric acid, which were mediated by inhibiting inflammatory signaling pathways."], "CopyrightInformation": "\u00a9 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Research Center of Natural Resources of Chinese Medicinal Materials and Ethnic Medicine, Jiangxi University of Chinese Medicine, Jiangxi province, Nanchang, 330004, People's Republic of China."}], "LastName": "Zhu", "ForeName": "Ji-Xiao", "Initials": "JX"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Research Center of Natural Resources of Chinese Medicinal Materials and Ethnic Medicine, Jiangxi University of Chinese Medicine, Jiangxi province, Nanchang, 330004, People's Republic of China."}], "LastName": "Yang", "ForeName": "Hai-Yan", "Initials": "HY"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Research Center of Natural Resources of Chinese Medicinal Materials and Ethnic Medicine, Jiangxi University of Chinese Medicine, Jiangxi province, Nanchang, 330004, People's Republic of China."}], "LastName": "Hu", "ForeName": "Wei-Qiong", "Initials": "WQ"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Chemical and Pharmaceutical Engineering, Huaqiao University, Fujian province, Xiamen, 361021, People's Republic of China."}], "LastName": "Cheng", "ForeName": "Jie", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Research Center of Natural Resources of Chinese Medicinal Materials and Ethnic Medicine, Jiangxi University of Chinese Medicine, Jiangxi province, Nanchang, 330004, People's Republic of China."}], "LastName": "Liu", "ForeName": "Yang", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Chemical and Pharmaceutical Engineering, Huaqiao University, Fujian province, Xiamen, 361021, People's Republic of China. litaoyi@hqu.edu.cn."}], "LastName": "Yi", "ForeName": "Li-Tao", "Initials": "LT"}, {"Identifier": ["0000-0003-1619-4308"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Humanities, Jiangxi University of Chinese Medicine, Jiangxi province, Nanchang, 330004, People's Republic of China. 55441626@qq.com."}], "LastName": "Cheng", "ForeName": "Hong-Yu", "Initials": "HY"}], "GrantList": [{"GrantID": "82060757", "Agency": "National Natural Science Foundation of China", "Country": ""}, {"GrantID": "GJJ190632", "Agency": "Science and Technology Research Project of Jiangxi Provincial Department of Education", "Country": ""}, {"GrantID": "2019A004", "Agency": "Science and Technology Project of Jiangxi Provincial Administration of Traditional Chinese Medicine", "Country": ""}, {"GrantID": "2019A258", "Agency": "Science and Technology Project of Jiangxi Provincial Administration of Traditional Chinese Medicine", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Inflammopharmacology", "NlmUniqueID": "9112626", "ISSNLinking": "0925-4692"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Drugs, Chinese Herbal"}, {"RegistryNumber": "0", "NameOfSubstance": "NLR Family, Pyrin Domain-Containing 3 Protein"}, {"RegistryNumber": "0", "NameOfSubstance": "Nlrp3 protein, mouse"}, {"RegistryNumber": "0", "NameOfSubstance": "Tlr4 protein, mouse"}, {"RegistryNumber": "0", "NameOfSubstance": "Toll-Like Receptor 4"}, {"RegistryNumber": "268B43MJ25", "NameOfSubstance": "Uric Acid"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": [], "DescriptorName": "Dose-Response Relationship, Drug"}, {"QualifierName": ["isolation & purification", "pharmacology", "therapeutic use"], "DescriptorName": "Drugs, Chinese Herbal"}, {"QualifierName": ["drug effects", "physiology"], "DescriptorName": "Homeostasis"}, {"QualifierName": ["drug therapy", "metabolism"], "DescriptorName": "Hyperuricemia"}, {"QualifierName": ["drug effects", "metabolism"], "DescriptorName": "Kidney"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": ["antagonists & inhibitors", "metabolism"], "DescriptorName": "NLR Family, Pyrin Domain-Containing 3 Protein"}, {"QualifierName": [], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": [], "DescriptorName": "Protein Structure, Secondary"}, {"QualifierName": ["drug effects", "physiology"], "DescriptorName": "Signal Transduction"}, {"QualifierName": ["antagonists & inhibitors", "metabolism"], "DescriptorName": "Toll-Like Receptor 4"}, {"QualifierName": ["metabolism", "toxicity"], "DescriptorName": "Uric Acid"}]}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Amezcua-Castillo LM, Juarez-Vicuna Y, Marquez-Velasco R, Amezcua-Guerra LM (2020) Activation status of NLRP3 Inflammasome in peripheral blood mononuclear cells from patients with Gout flare. J Clin Rheumatol 26:S208\u2013S212", "ArticleIdList": ["10.1097/RHU.0000000000001394"]}, {"Citation": "Anzai N, Endou H (2011) Urate transporters: an evolving field. Semin Nephrol 31:400\u2013409", "ArticleIdList": ["10.1016/j.semnephrol.2011.08.003"]}, {"Citation": "Azevedo VF, Kos IA, Vargas-Santos AB, da Rocha Castelar PG, Dos Santos Paiva E (2019) Benzbromarone in the treatment of gout. Adv Rheumatol 59:37", "ArticleIdList": ["10.1186/s42358-019-0080-x"]}, {"Citation": "De Nardo D, Latz E (2011) NLRP3 inflammasomes link inflammation and metabolic disease. Trends Immunol 32:373\u2013379", "ArticleIdList": ["10.1016/j.it.2011.05.004"]}, {"Citation": "Dong Y, Zhao T, Ai W, Zalloum WA, Kang D, Wu T, Liu X, Zhan P (2019) Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2016\u20132019). Expert Opin Ther Pat 29:871\u2013879", "ArticleIdList": ["10.1080/13543776.2019.1676727"]}, {"Citation": "Fan SH, Wang YY, Lu J, Zheng YL, Wu DM, Li MQ, Hu B, Zhang ZF, Cheng W, Shan Q (2014) Luteoloside suppresses proliferation and metastasis of hepatocellular carcinoma cells by inhibition of NLRP3 inflammasome. PLoS ONE 9:e89961", "ArticleIdList": ["10.1371/journal.pone.0089961"]}, {"Citation": "Guo LF, Chen X, Lei SS, Li B, Zhang NY, Ge HZ, Yang K, Lv GY, Chen SH (2020) Effects and mechanisms of Dendrobium officinalis six Nostrum for treatment of Hyperuricemia with Hyperlipidemia. Evid-Based Complement Alternate Med 2020:2914019"}, {"Citation": "Kanbay M, Solak Y, Afsar B, Nistor I, Aslan G, Caglayan OH, Aykanat A, Donciu MD, Lanaspa MA, Ejaz AA, Johnson RJ, Covic A (2017) Serum uric acid and risk for acute kidney injury following contrast. Angiology 68:132\u2013144", "ArticleIdList": ["10.1177/0003319716644395"]}, {"Citation": "Li Q, Tian Z, Wang M, Kou J, Wang C, Rong X, Li J, Xie X, Pang X (2019) Luteoloside attenuates neuroinflammation in focal cerebral ischemia in rats via regulation of the PPARgamma/Nrf2/NF-kappaB signaling pathway. Int Immunopharmacol 66:309\u2013316", "ArticleIdList": ["10.1016/j.intimp.2018.11.044"]}, {"Citation": "Lim H, Min DS, Park H, Kim HP (2018) Flavonoids interfere with NLRP3 inflammasome activation. Toxicol Appl Pharmacol 355:93\u2013102", "ArticleIdList": ["10.1016/j.taap.2018.06.022"]}, {"Citation": "Lin WQ, Xie JX, Wu XM, Yang L, Wang HD (2014) Inhibition of xanthine oxidase activity by gnaphalium affine extract. Chin Med Sci J 29:225\u2013230", "ArticleIdList": ["10.1016/S1001-9294(14)60075-4"]}, {"Citation": "Luan RL, Meng XX, Jiang W (2016) Protective effects of Apigenin against Paraquat-induced acute lung injury in mice. Inflammation 39:752\u2013758", "ArticleIdList": ["10.1007/s10753-015-0302-2"]}, {"Citation": "Ma C, Yang X, Lv Q, Yan Z, Chen Z, Xu D, Liu X, Yang W, Xing S (2020) Soluble uric acid induces inflammation via TLR4/NLRP3 pathway in intestinal epithelial cells. Iran J Basic Med Sci 23:744\u2013750", "ArticleIdList": ["32695290", "7351448"]}, {"Citation": "Nishitani Y, Yamamoto K, Yoshida M, Azuma T, Kanazawa K, Hashimoto T, Mizuno M (2013) Intestinal anti-inflammatory activity of luteolin: role of the aglycone in NF-kappaB inactivation in macrophages co-cultured with intestinal epithelial cells. BioFactors 39:522\u2013533", "ArticleIdList": ["10.1002/biof.1091"]}, {"Citation": "Otani N, Ouchi M, Hayashi K, Jutabha P, Anzai N (2017) Roles of organic anion transporters (OATs) in renal proximal tubules and their localization. Anat Sci Int 92:200\u2013206", "ArticleIdList": ["10.1007/s12565-016-0369-3"]}, {"Citation": "Pavelcova K, Bohata J, Pavlikova M, Bubenikova E, Pavelka K, Stiburkova B (2020) Evaluation of the influence of genetic variants of SLC2A9 (GLUT9) and SLC22A12 (URAT1) on the development of hyperuricemia and Gout. J Clin Med 9:2510", "ArticleIdList": ["10.3390/jcm9082510"]}, {"Citation": "Rahmi EP, Kumolosasi E, Jalil J, Husain K, Buang F, Abd Razak AF, Jamal JA (2020) Anti-hyperuricemic and anti-inflammatory effects of Marantodes pumilum as potential treatment for Gout. Front Pharmacol 11:289", "ArticleIdList": ["10.3389/fphar.2020.00289"]}, {"Citation": "Romero CA, Remor A, Latini A, De Paul AL, Torres AI, Mukdsi JH (2017) Uric acid activates NRLP3 inflammasome in an in-vivo model of epithelial to mesenchymal transition in the kidney. J Mol Histol 48:209\u2013218", "ArticleIdList": ["10.1007/s10735-017-9720-9"]}, {"Citation": "Serrano JL, Figueiredo J, Almeida P, Silvestre S (2020) From Xanthine oxidase inhibition to in vivo hypouricemic effect: an integrated overview of in vitro and in vivo studies with focus on natural molecules and analogues. Evid-Based Complement Alternat Med 2020:9531725", "ArticleIdList": ["10.1155/2020/9531725"]}, {"Citation": "Shekelle PG, Newberry SJ, FitzGerald JD, Motala A, O\u2019Hanlon CE, Tariq A, Okunogbe A, Han D, Shanman R (2017) Management of Gout: a systematic review in support of an American College of Physicians Clinical Practice Guideline. Ann Intern Med 166:37\u201351", "ArticleIdList": ["10.7326/M16-0461"]}, {"Citation": "Shen R, Ma L, Zheng Y (2020) Anti-inflammatory effects of luteolin on acute gouty arthritis rats via TLR/MyD88/NF-kappaB pathway. Zhong Nan Da Xue Xue Bao Yi Xue Ban 45:115\u2013122", "ArticleIdList": ["32386034"]}, {"Citation": "So A (2007a) New knowledge on the pathophysiology and therapy of gout. Z Rheumatol 66(562):564\u2013567"}, {"Citation": "So A (2007b) Recent advances in the pathophysiology of hyperuricemia and gout. Rev Med Suisse 3(720):722\u2013724"}, {"Citation": "Su HY, Yang C, Liang D, Liu HF (2020) Research advances in the mechanisms of hyperuricemia-induced renal injury. Biomed Res Int 2020:5817348", "ArticleIdList": ["32685502", "7336201"]}, {"Citation": "Torres RJ, Puig JG (2018) GLUT9 influences uric acid concentration in patients with Lesch-Nyhan disease. Int J Rheum Dis 21:1270\u20131276", "ArticleIdList": ["10.1111/1756-185X.13323"]}, {"Citation": "Tsai CW, Lin SY, Kuo CC, Huang CC (2017) Serum uric acid and progression of kidney disease: a longitudinal analysis and mini-review. PLoS ONE 12:e0170393", "ArticleIdList": ["10.1371/journal.pone.0170393"]}, {"Citation": "Wang K, Hu L, Chen JK (2018) RIP3-deficience attenuates potassium oxonate-induced hyperuricemia and kidney injury. Biomed Pharmacother 101:617\u2013626", "ArticleIdList": ["10.1016/j.biopha.2018.02.010"]}, {"Citation": "Xiong W, Zhang H, Wen L, Wang X, Zhong G, Shi Y, DU, X. and Zhu, J. (2018) Effect of Lagotis brachystachya Maxim extract on xanthine oxidase and renal urate transporters in hyperuricemia mice. Chin J New Drugs 27:1538\u20131543"}, {"Citation": "Xu L, Shi Y, Zhuang S, Liu N (2017) Recent advances on uric acid transporters. Oncotarget 8:100852\u2013100862", "ArticleIdList": ["10.18632/oncotarget.20135"]}, {"Citation": "Yamagata K, Hashiguchi K, Yamamoto H, Tagami M (2019) Dietary Apigenin reduces induction of LOX-1 and NLRP3 expression, Leukocyte Adhesion, and Acetylated low-density lipoprotein uptake in human endothelial cells exposed to Trimethylamine-N-Oxide. J Cardiovasc Pharmacol 74:558\u2013565", "ArticleIdList": ["10.1097/FJC.0000000000000747"]}, {"Citation": "Yan J, Zhang G, Hu Y, Ma Y (2013) Effect of luteolin on xanthine oxidase: inhibition kinetics and interaction mechanism merging with docking simulation. Food Chem 141:3766\u20133773", "ArticleIdList": ["10.1016/j.foodchem.2013.06.092"]}, {"Citation": "Zhang X, Yang X, Wang M, Li X, Xia Q, Xu S, Xu J, Cai G, Wang L, Xin L, Zou Y, Pan F (2016) Association between SLC2A9 (GLUT9) gene polymorphisms and gout susceptibility: an updated meta-analysis. Rheumatol Int 36:1157\u20131165", "ArticleIdList": ["10.1007/s00296-016-3503-6"]}, {"Citation": "Zhu J, Shi Y, Cheng H, Wang H, Wang R, Li M (2019) Chemical constituents from Lagotis brachystachy. J Chin Med Mater 42:552\u2013555"}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "2", "Day": "27"}, {"Year": "2021", "Month": "6", "Day": "26"}, {"Year": "2021", "Month": "7", "Day": "11", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "1", "Day": "1", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "7", "Day": "10", "Hour": "6", "Minute": "25"}], "PublicationStatus": "ppublish", "ArticleIdList": ["34244900", "10.1007/s10787-021-00844-5", "10.1007/s10787-021-00844-5"]}}], "PubmedBookArticle": []}